This HTML5 document contains 117 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n25http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/drugbank/dosage/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01018/identifier/pharmgkb/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01018/identifier/wikipedia/
n29http://linked.opendata.cz/resource/drugbank/drug/DB01018/identifier/kegg-compound/
n26http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB01018/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01018/identifier/pubchem-substance/
n30http://linked.opendata.cz/resource/drugbank/drug/DB01018/identifier/drugbank/
n6http://linked.opendata.cz/resource/drugbank/patent/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n28http://linked.opendata.cz/resource/drugbank/drug/DB01018/identifier/iuphar/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
n14http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n31http://linked.opendata.cz/resource/drugbank/drug/DB01018/identifier/guide-to-pharmacology/
n3http://linked.opendata.cz/ontology/drugbank/
n24http://www.drugs.com/cdi/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01018/identifier/national-drug-code-directory/
n9http://linked.opendata.cz/resource/drugbank/property/
n22http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/atc/
n27http://linked.opendata.cz/resource/drugbank/drug/DB01018/identifier/chemspider/
n16http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01018
rdf:type
n3:Drug
n3:description
A centrally acting antihypertensive agent. The drug lowers both systolic and diastolic blood pressure by activating the central nervous system alpha-2 adrenoreceptors, which results in reduced sympathetic outflow leading to reduced vascular tone. Its adverse reactions include dry mouth, sedation, and constipation. [PubChem]
n3:dosage
n23:271B5380-363D-11E5-9242-09173F13E4C5 n23:271B5381-363D-11E5-9242-09173F13E4C5 n23:271B5382-363D-11E5-9242-09173F13E4C5 n23:271B5383-363D-11E5-9242-09173F13E4C5 n23:271B5384-363D-11E5-9242-09173F13E4C5 n23:271B5385-363D-11E5-9242-09173F13E4C5 n23:271B5386-363D-11E5-9242-09173F13E4C5
n3:group
investigational approved
n3:halfLife
17 hours (range 10-30 hours)
n3:indication
For use alone or in combination with other classes of antihypertensive agents in the management of hypertension. Has also been used for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients.
n3:manufacturer
n4:271B536F-363D-11E5-9242-09173F13E4C5 n4:271B5370-363D-11E5-9242-09173F13E4C5 n4:271B536D-363D-11E5-9242-09173F13E4C5 n4:271B536E-363D-11E5-9242-09173F13E4C5 n4:271B5371-363D-11E5-9242-09173F13E4C5 n4:271B536C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n19:DB01018 n26:DB01018
dcterms:title
Guanfacine
adms:identifier
n8:Guanfacine n10:3519 n11:46506169 n12:55567-051-18 n13:PA449825 n27:3399 n28:522 n29:C07037 n30:DB01018 n31:522
n3:mechanismOfAction
Guanfacine selectively stimulates central alpha(2)-adrenergic receptors, resulting in inhibition of sympathetic vasomotor centers, which contributes predominantly to the hypotensive effects of the drug. Central effects of guanfacine lead to reduced peripheral sympathetic nerve impulses from the vasomotor center to the heart and blood vessels. This results in a decrease in peripheral vascular resistance and a reduction in heart rate. The stimulation of peripheral alpha(2)-adrenergic receptors may also contribute to hypotensive effects.
n3:packager
n4:271B5363-363D-11E5-9242-09173F13E4C5 n4:271B5364-363D-11E5-9242-09173F13E4C5 n4:271B535E-363D-11E5-9242-09173F13E4C5 n4:271B535F-363D-11E5-9242-09173F13E4C5 n4:271B535C-363D-11E5-9242-09173F13E4C5 n4:271B535D-363D-11E5-9242-09173F13E4C5 n4:271B535B-363D-11E5-9242-09173F13E4C5 n4:271B536B-363D-11E5-9242-09173F13E4C5 n4:271B5369-363D-11E5-9242-09173F13E4C5 n4:271B536A-363D-11E5-9242-09173F13E4C5 n4:271B5367-363D-11E5-9242-09173F13E4C5 n4:271B5368-363D-11E5-9242-09173F13E4C5 n4:271B5365-363D-11E5-9242-09173F13E4C5 n4:271B5366-363D-11E5-9242-09173F13E4C5 n4:271B5361-363D-11E5-9242-09173F13E4C5 n4:271B5362-363D-11E5-9242-09173F13E4C5 n4:271B5360-363D-11E5-9242-09173F13E4C5 n4:271B535A-363D-11E5-9242-09173F13E4C5 n4:271B5358-363D-11E5-9242-09173F13E4C5 n4:271B5359-363D-11E5-9242-09173F13E4C5 n4:271B5357-363D-11E5-9242-09173F13E4C5
n3:patent
n6:6811794 n6:5854290
n3:routeOfElimination
In individuals with normal renal function, guanfacine and its metabolites are excreted primarily in the urine.
n3:synonym
Guanfacinum Guanfacina Estulic
n3:toxicity
Symptoms of overdose include drowsiness, lethargy, bradycardia and hypotension. LD<sub>50</sub>=165mg/kg (orally in mice)
n3:volumeOfDistribution
* 6.3 L/kg
n3:proteinBinding
Approximately 70% bound to plasma proteins, independent of drug concentration.
n3:salt
n3:synthesisReference
U.S. Patent 3,632,645.
n14:hasConcept
n15:M0024935
foaf:page
n22:gua1657.shtml n24:guanfacine.html n25:guanfacine.htm
n3:IUPAC-Name
n9:271B538B-363D-11E5-9242-09173F13E4C5
n3:InChI
n9:271B5391-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n9:271B5390-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n9:271B538D-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n9:271B538E-363D-11E5-9242-09173F13E4C5
n3:SMILES
n9:271B538F-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n9:271B5389-363D-11E5-9242-09173F13E4C5 n9:271B53A1-363D-11E5-9242-09173F13E4C5
n3:logP
n9:271B538A-363D-11E5-9242-09173F13E4C5 n9:271B5387-363D-11E5-9242-09173F13E4C5 n9:271B53A3-363D-11E5-9242-09173F13E4C5
n3:logS
n9:271B5388-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n17:C02AC02
n3:H-Bond-Acceptor-Count
n9:271B5397-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n9:271B5398-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n9:271B5392-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n9:271B5393-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n9:271B5395-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n9:271B5394-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n9:271B5396-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapid and complete, with an oral bioavailability of approximately 80%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
29110-47-2
n3:category
n3:containedIn
n5:271B5374-363D-11E5-9242-09173F13E4C5 n5:271B5375-363D-11E5-9242-09173F13E4C5 n5:271B5372-363D-11E5-9242-09173F13E4C5 n5:271B5373-363D-11E5-9242-09173F13E4C5 n5:271B537C-363D-11E5-9242-09173F13E4C5 n5:271B537D-363D-11E5-9242-09173F13E4C5 n5:271B537A-363D-11E5-9242-09173F13E4C5 n5:271B537B-363D-11E5-9242-09173F13E4C5 n5:271B5378-363D-11E5-9242-09173F13E4C5 n5:271B5379-363D-11E5-9242-09173F13E4C5 n5:271B5376-363D-11E5-9242-09173F13E4C5 n5:271B5377-363D-11E5-9242-09173F13E4C5 n5:271B537E-363D-11E5-9242-09173F13E4C5 n5:271B537F-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n9:271B539D-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n9:271B539F-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n9:271B53A0-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n9:271B53A2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n9:271B539C-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n9:271B539B-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n9:271B539E-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n9:271B538C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n9:271B5399-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n9:271B539A-363D-11E5-9242-09173F13E4C5